This segment focuses on the OCS LUNG system, a portable ex-vivo lung perfusion system designed to preserve and assess donor lungs for double-lung transplantation. Research and development efforts concentrate on improving lung preservation techniques, optimizing perfusion solutions, and enhancing monitoring capabilities. The technology utilizes a proprietary system to replicate near-physiologic conditions for donor lungs outside the body, extending their viability and improving transplant outcomes. This segment addresses the critical need for viable donor lungs, impacting patients with end-stage lung disease. Market positioning is strong due to the innovative nature of the technology and its ability to increase the number of transplantable lungs. Future opportunities include expanding the OCS LUNG system's capabilities and exploring its use in other lung-related therapies. Regulatory and clinical aspects involve rigorous testing and FDA approval processes to ensure patient safety and efficacy. Partnerships with transplant centers and hospitals are crucial for the successful implementation and adoption of the OCS LUNG system.

This segment centers on the OCS Heart system, a technology for extracorporeal perfusion and preservation of donor hearts. Research and development activities are focused on refining the perfusion process, optimizing the preservation solution, and enhancing the monitoring of heart function during ex-vivo preservation. The OCS Heart system utilizes advanced technology to maintain the heart in a near-physiologic state, allowing for extended preservation times and improved assessment of heart viability. This segment directly addresses the challenges of heart transplantation, providing a means to increase the number of viable donor hearts and improve patient outcomes. The company's market position is strengthened by the OCS Heart system's ability to improve the quality and availability of donor hearts. Future growth opportunities include expanding the system's capabilities and exploring its use in other cardiac-related therapies. Regulatory and clinical aspects involve stringent testing and FDA approval to ensure patient safety and efficacy. Partnerships with cardiac transplant centers and hospitals are essential for the successful implementation and adoption of the OCS Heart system.

This segment is dedicated to the OCS Liver system, which focuses on the preservation of donor livers. Research and development efforts are directed towards optimizing the perfusion process, refining the preservation solution, and enhancing the monitoring of liver function during ex-vivo preservation. The OCS Liver system employs advanced technology to maintain the liver in a near-physiologic state, extending its viability and improving the assessment of liver quality. This segment addresses the critical need for viable donor livers, impacting patients with end-stage liver disease. The company's market position is enhanced by the OCS Liver system's ability to improve the quality and availability of donor livers. Future growth opportunities include expanding the system's capabilities and exploring its use in other liver-related therapies. Regulatory and clinical aspects involve rigorous testing and FDA approval to ensure patient safety and efficacy. Partnerships with liver transplant centers and hospitals are crucial for the successful implementation and adoption of the OCS Liver system.